These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 17335684)

  • 41. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Myeloma: making sense of a complex blood cancer.
    Kelly MB; Meenaghan T; Dowling M
    Br J Nurs; 2010 Dec 9-2011 Jan 13; 19(22):1415-21. PubMed ID: 21139523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel agents for relapsed and/or refractory multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in treatment for relapses and refractory multiple myeloma.
    Richards T; Weber D
    Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pomalidomide in the treatment of relapsed multiple myeloma.
    Forsberg PA; Mark TM
    Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnosis and therapy of multiple myeloma.
    Palumbo A; Cerrato C
    Korean J Intern Med; 2013 May; 28(3):263-73. PubMed ID: 23682217
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
    Richardson PG; Mitsiades C; Ghobrial I; Anderson K
    Curr Opin Oncol; 2006 Nov; 18(6):598-608. PubMed ID: 16988581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.
    Morgan G
    Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An update on drug combinations for treatment of myeloma.
    Srikanth M; Davies FE; Morgan GJ
    Expert Opin Investig Drugs; 2008 Jan; 17(1):1-12. PubMed ID: 18095914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
    Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
    J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proteasome inhibition in multiple myeloma.
    Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
    Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
    Jagannath S; Dimopoulos MA; Lonial S
    Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New treatments for multiple myeloma.
    Richardson PG; Schlossman R; Hideshima T; Anderson KC
    Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overview of drug therapy for multiple myeloma.
    Saunders G
    J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
    Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
    Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New treatments for myeloma.
    Azaïs I; Brault R; Debiais F
    Joint Bone Spine; 2010 Jan; 77(1):20-6. PubMed ID: 20031467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel treatment approaches for patients with multiple myeloma.
    Sinha R; Kaufman JL; Lonial S
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):281-8. PubMed ID: 16507205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted therapy of multiple myeloma.
    Kyle RA
    Hematology; 2012 Apr; 17 Suppl 1():S125-8. PubMed ID: 22507799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.